CYCLO THERAPEUTICS, INC.: 10-Q filed 2020-11-12
What CYCLO THERAPEUTICS, INC. reported in its quarterly report filed 2020-11-12 (fiscal Q3 2020): 24 published measures, 66 facts as tagged in accession 0001437749-20-023608.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-11-12
- Fiscal period
- fiscal Q3 2020
- Accession
- 0001437749-20-023608 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 4,132,436 | USD | |
| At 2019-12-31 | 4,113,228 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | -524,533 | USD | |
| At 2020-06-30 | -1,920,039 | USD | |
| At 2020-03-31 | -1,698,010 | USD | |
| At 2019-12-31 | 935,982 | USD | |
| At 2019-09-30 | 3,483,247 | USD | |
| At 2019-06-30 | 4,840,009 | USD | |
| At 2019-03-31 | -781,580 | USD | |
| At 2018-12-31 | 992,524 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 2,237,624 | USD | |
| At 2019-12-31 | 2,783,719 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | -1,435,609 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -6,261,993 | USD | 274 |
| 2020-04-01 to 2020-06-30 | -2,192,392 | USD | 91 |
| 2020-01-01 to 2020-03-31 | -2,633,992 | USD | 91 |
| 2019-01-01 to 2019-12-31 | -7,533,000 | USD | 365 |
| 2019-07-01 to 2019-09-30 | -1,625,341 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -4,897,518 | USD | 273 |
| 2019-04-01 to 2019-06-30 | -1,368,011 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -1,904,166 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | -5,478,838 | USD | 274 |
| 2019-01-01 to 2019-09-30 | -4,369,478 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 53,127 | USD | 274 |
| 2019-01-01 to 2019-09-30 | 1,324 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 4,960,002 | USD | 274 |
| 2019-01-01 to 2019-09-30 | 7,119,662 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | -27,259 | USD | 274 |
| 2019-01-01 to 2019-09-30 | 26,619 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | -31,382,226 | USD | |
| At 2019-12-31 | -25,120,233 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 57,320 | USD | |
| At 2019-12-31 | 13,546 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | -1,435,999 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -6,279,942 | USD | 274 |
| 2019-07-01 to 2019-09-30 | -1,628,625 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -4,906,699 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 3,972,040 | USD | |
| At 2019-12-31 | 3,958,069 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 4,559,990 | USD | |
| At 2019-12-31 | 3,141,120 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 85,504 | USD | |
| At 2019-12-31 | 143,429 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 421,324 | USD | |
| At 2019-12-31 | 242,630 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | 1,086,753 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 4,859,794 | USD | 274 |
| 2019-07-01 to 2019-09-30 | 941,539 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 3,071,113 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 169,876,130 | shares | |
| At 2019-12-31 | 121,564,990 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 30,840,706 | USD | |
| At 2019-12-31 | 26,044,060 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 38,348 | USD | |
| At 2019-12-31 | 51,017 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | -1,435,609 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -6,261,993 | USD | 274 |
| 2019-07-01 to 2019-09-30 | -1,625,341 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -4,897,518 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 9,353 | USD | 274 |
| 2019-01-01 to 2019-09-30 | 4,261 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 224 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | -57,925 | USD | 274 |
| 2019-01-01 to 2019-09-30 | -44,302 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 178,694 | USD | 274 |
| 2019-01-01 to 2019-09-30 | -32,420 | USD | 273 |
Inspect the source
- Entity
- CYCLO THERAPEUTICS, INC. / CIK 0000922247
- Captured
- 2026-09-21T17:17:43.874Z
- SEC response SHA-256
00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))